Psoriasis is a chronic skin disorder that causes erythema, scales, pruritis, and painful plaques. The immune-mediated disease gets aggravated by pro-inflammatory cytokines. The patients risk various comorbidities like arthritis, diabetes, IBS, obesity, heart, and liver diseases. This study relates psoriasis with them and also explores the need for new therapies.

The study subjects were patients with moderate to severe psoriasis. The study reviewed existing literature for assessing the ability of biological therapies and the role of treatment in relieving pain due to inflammation.

The evidence highlights the significance of post-inflammation damage control. Prevention of future inflammatory damage and comorbidities is also a potential goal. The researchers found the early usage of biological therapies to be essential. The data is also optimistic about reversing existing inflammatory damage. Reversing the signs and symptoms of comorbidities is also a possible and attainable goal.

Systemic, targeted treatment can reduce the risk of future damage and comorbidities in moderate and severe psoriasis patients. But, reversal treatment evidence is not well-developed. Larger, well-designed studies are necessary to firmly establish the link between types of improvements and systemic inflammation reductions. Overall, biologics have potential, and short-term reversal prospects look good.